AU2012371260A8 - Predicitive biomarker for cancer treatment with ADCC enhanced antibodies - Google Patents
Predicitive biomarker for cancer treatment with ADCC enhanced antibodiesInfo
- Publication number
- AU2012371260A8 AU2012371260A8 AU2012371260A AU2012371260A AU2012371260A8 AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8 AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8
- Authority
- AU
- Australia
- Prior art keywords
- predicitive
- biomarker
- cancer treatment
- enhanced antibodies
- adcc enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/053600 WO2013127465A1 (en) | 2012-03-02 | 2012-03-02 | Predicitive biomarker for cancer treatment with adcc enhanced antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2012371260A1 AU2012371260A1 (en) | 2014-07-10 |
AU2012371260A8 true AU2012371260A8 (en) | 2014-09-18 |
Family
ID=45814493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012371260A Abandoned AU2012371260A1 (en) | 2012-03-02 | 2012-03-02 | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP2015511702A (en) |
KR (1) | KR20140130455A (en) |
AU (1) | AU2012371260A1 (en) |
BR (1) | BR112014018374A8 (en) |
CA (1) | CA2860369A1 (en) |
MX (1) | MX2014010379A (en) |
RU (1) | RU2014138586A (en) |
WO (1) | WO2013127465A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
TWI693073B (en) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
CN113933504A (en) * | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | Patient-administered GPC3 targeted therapeutics effective for GPC3 targeted therapeutic treatment |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE503496T1 (en) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DK1071700T3 (en) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
PL222222B1 (en) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Method for polypeptide production |
EP2404937A1 (en) | 2005-02-07 | 2012-01-11 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
AR062223A1 (en) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
ATE501436T1 (en) * | 2006-09-13 | 2011-03-15 | Glycode | METHOD FOR STUDYING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY |
AR075982A1 (en) * | 2009-03-31 | 2011-05-11 | Roche Glycart Ag | COMBINATION THERAPY OF A AFUCOSILATED ANTIBODY AND ONE OR MORE OF THE SELECTED CYTOKINS OF GM-CSF HUMAN, M-CSF HUMAN AND / OR IL-3 HUMAN AND COMPOSITION |
JP5706913B2 (en) * | 2009-12-16 | 2015-04-22 | 日立化成株式会社 | Method for characterizing host immune function by ex vivo induction of aggressive and protective immune markers |
-
2012
- 2012-03-02 MX MX2014010379A patent/MX2014010379A/en unknown
- 2012-03-02 BR BR112014018374A patent/BR112014018374A8/en not_active IP Right Cessation
- 2012-03-02 AU AU2012371260A patent/AU2012371260A1/en not_active Abandoned
- 2012-03-02 KR KR20147024440A patent/KR20140130455A/en not_active Application Discontinuation
- 2012-03-02 CA CA2860369A patent/CA2860369A1/en not_active Abandoned
- 2012-03-02 WO PCT/EP2012/053600 patent/WO2013127465A1/en active Application Filing
- 2012-03-02 RU RU2014138586A patent/RU2014138586A/en not_active Application Discontinuation
- 2012-03-02 JP JP2014559106A patent/JP2015511702A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013127465A1 (en) | 2013-09-06 |
KR20140130455A (en) | 2014-11-10 |
CA2860369A1 (en) | 2013-09-06 |
RU2014138586A (en) | 2016-04-20 |
BR112014018374A8 (en) | 2017-07-11 |
MX2014010379A (en) | 2015-05-15 |
AU2012371260A1 (en) | 2014-07-10 |
JP2015511702A (en) | 2015-04-20 |
BR112014018374A2 (en) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2015012122A (en) | Antibody drug conjugates and corresponding antibodies. | |
MX2016002826A (en) | Anti-b7-h1 antibodies for treating tumors. | |
AU2011338480A8 (en) | Humanized antibodies to LIV-1 and use of same to treat cancer | |
GEP20217331B (en) | Anti-tigit antibodies | |
NZ702748A (en) | Cd33 antibodies and use of same to treat cancer | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MX2014009751A (en) | Antibodies to integrin avvb6 and use of same to treat cancer. | |
UA114277C2 (en) | Anti-angiogenesis therfpy for the treatment of ovarian cancer | |
PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
IN2014DN05885A (en) | ||
TR201909951T4 (en) | A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer. | |
AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies | |
PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
MX347463B (en) | Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody. | |
IN2014DN09717A (en) | ||
MX2014006187A (en) | Compositions and methods for prostate cancer analysis. | |
WO2013052108A3 (en) | Methods and compositions for the treatment and diagnosis of ovarian cancer | |
MX2019002818A (en) | Methods of detecting anti-leptin neutralizing antibodies. | |
WO2012106473A8 (en) | Dosing for treatment with anti-egfl7 antibodies | |
MX362497B (en) | Methods for treatment of gastric cancer. | |
PH12014502461A1 (en) | Biomarkers for iap inhibitor therapy | |
IN2014CN02496A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 28 , NO 27 , PAGE(S) 3655 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ROCHE GLYCART AG, APPLICATION NO. 2012371260, UNDER INID (71) CORRECT THE APPLICANT NAME TO ROCHE GLYCART AG |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |